Movement Alert｜Abivax S.A. Rises 6.37% Overnight, Market Momentum Continues After Upsized $800 Million Equity Offering Priced

Market Focus07-02

On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.

On the news front, the company completed the pricing of an underwritten public offering of 6.4 million American Depositary Shares at $125 each, totaling $800 million — upsized from an initially announced $600 million, signaling robust institutional subscription demand. Proceeds will primarily fund the potential commercialization of lead drug candidate obefazimod in the United States, as well as clinical development for ulcerative colitis and Crohn's disease.

The upsizing follows a sharp rebound of over 38% after the company reported positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and effectively addressed prior concerns over malignancy cases in the 50 mg cohort. The stock continues to trade well above the $125 offering price, reflecting sustained market confidence in the company's near-term FDA submission plans and commercial outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157301370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 15:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157301370","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 6.37% Overnight, Market Momentum Continues After Upsized $800 Million Equity Offering Priced","media":"Market Focus","content":"<p><p>On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.</p><p>On the news front, the company completed the pricing of an underwritten public offering of 6.4 million American Depositary Shares at $125 each, totaling $800 million — upsized from an initially announced $600 million, signaling robust institutional subscription demand. Proceeds will primarily fund the potential commercialization of lead drug candidate obefazimod in the United States, as well as clinical development for ulcerative colitis and Crohn's disease.</p><p>The upsizing follows a sharp rebound of over 38% after the company reported positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and effectively addressed prior concerns over malignancy cases in the 50 mg cohort. The stock continues to trade well above the $125 offering price, reflecting sustained market confidence in the company's near-term FDA submission plans and commercial outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 6.37% Overnight, Market Momentum Continues After Upsized $800 Million Equity Offering Priced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 6.37% Overnight, Market Momentum Continues After Upsized $800 Million Equity Offering Priced\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 15:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.</p><p>On the news front, the company completed the pricing of an underwritten public offering of 6.4 million American Depositary Shares at $125 each, totaling $800 million — upsized from an initially announced $600 million, signaling robust institutional subscription demand. Proceeds will primarily fund the potential commercialization of lead drug candidate obefazimod in the United States, as well as clinical development for ulcerative colitis and Crohn's disease.</p><p>The upsizing follows a sharp rebound of over 38% after the company reported positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and effectively addressed prior concerns over malignancy cases in the 50 mg cohort. The stock continues to trade well above the $125 offering price, reflecting sustained market confidence in the company's near-term FDA submission plans and commercial outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1157301370","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157301370","pubTimestamp":1782975954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.On the news front, the company completed the pricing of an underwritten public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.隔夜涨6.37%，增发8亿美元股票定价后市场势头持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.On the news front, the company completed the pricing of an underwritten public offering of 6.4 million American Depositary Shares at $125 each, totaling $800 million — upsized from an initially announced $600 million, signaling robust institutional subscription demand. Proceeds will primarily fund the potential commercialization of lead drug candidate obefazimod in the United States, as well as clinical development for ulcerative colitis and Crohn's disease.The upsizing follows a sharp rebound of over 38% after the company reported positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and effectively addressed prior concerns over malignancy cases in the 50 mg cohort. The stock continues to trade well above the $125 offering price, reflecting sustained market confidence in the company's near-term FDA submission plans and commercial outlook.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157301370","isCrawlerRequest":true}